The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Self-citationLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Self-citationThe exploration of macrocycles for drug discovery — an underexploited structural class
Driggers, E. M., Hale, S. P., Lee, J., & Terrett, N. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2590 · Cited by 1,370
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Dobson, C. M. (2004) · Nature · doi:10.1038/nature03192 · Cited by 1,003
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Self-citationStructure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Koch, M. A., Schuffenhauer, A., Scheck, M., Wetzel, S., Casaulta, M., Odermatt, A., Ertl, P., & Waldmann, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503647102 · Cited by 544
Perola, E., & Charifson, P. S. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030563w · Cited by 447
Wei, G., Xi, W., Nussinov, R., & Ma, B. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00562 · Cited by 436
Molecular obesity, potency and other addictions in drug discovery
Hann, M. M. (2011) · MedChemComm · doi:10.1039/c1md00017a · Cited by 363
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Alex, A., Millan, D. S., Perez, M., Wakenhut, F., & Whitlock, G. A. (2011) · MedChemComm · doi:10.1039/c1md00093d · Cited by 329
Park, C.-M., Bruncko, M., Adickes, J., Bauch, J., Ding, H., Kunzer, A., Marsh, K. C., Nimmer, P., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 300
Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery
Pérot, S., Sperandio, O., Miteva, M. A., Camproux, A.-C., & Villoutreix, B. O. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.015 · Cited by 276
Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery?
Bisson, J., McAlpine, J. B., Friesen, J. B., Chen, S.-N., Graham, J., & Pauli, G. F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01009 · Cited by 247
DNA-Encoded Chemical Libraries: Advancing beyond Conventional Small-Molecule Libraries
Franzini, R. M., Neri, D., & Scheuermann, J. (2014) · Accounts of Chemical Research · doi:10.1021/ar400284t · Cited by 243
Biophysics of protein evolution and evolutionary protein biophysics
Sikosek, T., & Chan, H. S. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0419 · Cited by 222
El Tayar, N., Mark, A. E., Vallat, P., Brunne, R. M., Testa, B., & van Gunsteren, W. F. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00076a002 · Cited by 215
Quantifying the Relationships among Drug Classes
Hert, J., Keiser, M. J., Irwin, J. J., Oprea, T. I., & Shoichet, B. K. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci8000259 · Cited by 169
Properties and Architecture of Drugs and Natural Products Revisited
Grabowski, K., & Schneider, G. (2007) · Current Chemical Biology · doi:10.2174/2212796810701010115 · Cited by 132
Kim, Y.-K., Arai, M. A., Arai, T., Lamenzo, J. O., Dean, E. F., Patterson, N. J., Clemons, P. A., & Schreiber, S. L. (2004) · Journal of the American Chemical Society · doi:10.1021/ja048170p · Cited by 130
CRAMER, R. D. I., Jilek, R. J., Güssregen, S., Clark, S. J., Wendt, B., & Clark, R. D. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049501b · Cited by 130
Andrec, M., Snyder, D. A., Zhou, Z., Young, J. Y., Montelione, G. T., & Levy, R. M. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21507 · Cited by 117
Fitzpatrick, A. W. P., Knowles, T. P. J., Waudby, C. A., Vendruscolo, M., & Dobson, C. M. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002169 · Cited by 116
Belema, M., & Meanwell, N. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500335h · Cited by 112
Energy landscapes of functional proteins are inherently risky
Gershenson, A., Gierasch, L. M., Pastore, A., & Radford, S. E. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1670 · Cited by 103
Johnson, D. K., & Karanicolas, J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002951 · Cited by 98
Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes
Dančík, V., Seiler, K. P., Young, D. W., Schreiber, S. L., & Clemons, P. A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102798t · Cited by 88
Estimating the prevalence of protein sequences adopting functional enzyme folds
Axe, D. D. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.06.058 · Cited by 86 · cited 1×
“The clear evidence that biologically active compounds exhibit small world clustering behavior [5] indicates that the second alternative is correct, namely that most of chemical space is “empty” and devoid of biologically active compounds and correspondingly thatmost of protein sequence space is devoid of functional ac…”
BackgroundThe Recognition of Identical Ligands by Unrelated Proteins
Barelier, S., Sterling, T., O’Meara, M. J., & Shoichet, B. K. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00683 · Cited by 81
Analysis of Physicochemical Properties for Drugs of Natural Origin
Camp, D., Garavelas, A., & Campitelli, M. R. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00255 · Cited by 76
A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors
Villoutreix, B. O., Labbé, C. M., Lagorce, D., Laconde, G., & Spérandio, O. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651571 · Cited by 74
Patel, S. C., Bradley, L. H., Jinadasa, S. P., & Hecht, M. H. (2009) · Protein Science · doi:10.1002/pro.147 · Cited by 73
Interplay of physics and evolution in the likely origin of protein biochemical function
Skolnick, J., & Gao, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300011110 · Cited by 67
Choo, E. F., Boggs, J. W., Zhu, C., Lubach, J. W., Catron, N. D., Jenkins, G. J., Souers, A. J., & Voorman, R. L. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055053 · Cited by 63
A Common Protein Fold Topology Shared by Flavonoid Biosynthetic Enzymes and Therapeutic Targets
McArdle, B. M., Campitelli, M. R., & Quinn, R. J. (2005) · Journal of Natural Products · doi:10.1021/np050229y · Cited by 61
How Much Binding Affinity Can be Gained by Filling a Cavity?
Kawasaki, Y., Chufán, E. E., Lafont, V., Hidaka, K., Kiso, Y., Amzel, L. M., & Freire, E. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00921.x · Cited by 50
Form follows function: Shape analysis of protein cavities for receptor‐based drug design
Weisel, M., Proschak, E., Kriegl, J. M., & Schneider, G. (2009) · PROTEOMICS · doi:10.1002/pmic.200800092 · Cited by 49
Which three-dimensional characteristics make efficient inhibitors of protein–protein interactions?
Kuenemann, M. A., Bourbon, L. M. L., Labbé, C. M., Villoutreix, B. O., & Sperandio, O. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500487q · Cited by 42
The chemist as astronaut: Searching for biologically useful space in the chemical universe
Triggle, D. J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.015 · Cited by 38
Merging chemical and biological space: Structural mapping of enzyme binding pocket space
Weskamp, N., Hüllermeier, E., & Klebe, G. (2008) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22345 · Cited by 38
Parallel Worlds of Public and Commercial Bioactive Chemistry Data
Lipinski, C. A., Litterman, N. K., Southan, C., Williams, A. J., Clark, A. M., & Ekins, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011308 · Cited by 36
Self-citationOn the enthalpic preference of fragment binding
Ferenczy, G. G., & Keserű, G. M. (2015) · MedChemComm · doi:10.1039/c5md00542f · Cited by 34
Warfarin: an environment‐dependent switchable molecular probe
Nicholls, I. A., Karlsson, B. C. G., Rosengren, A. M., & Henschel, H. (2010) · Journal of Molecular Recognition · doi:10.1002/jmr.1058 · Cited by 26
Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery
Zauhar, R. J., Gianti, E., & Welsh, W. J. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9698-7 · Cited by 18
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
Wendt, M. D. (2012) · Topics in medicinal chemistry · doi:10.1007/978-3-642-28965-1_7 · Cited by 18
Considerations of Protein Subpockets in Fragment‐Based Drug Design
Bartolowits, M. D., & Davisson, V. J. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12631 · Cited by 14
Stuck in a rut with old chemistry
Boström, J., & Brown, D. G. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.017 · Cited by 12
Introduction to Hepatitis C Virus (HCV) Therapies Special Thematic Issue
Meanwell, N. A., & Watkins, W. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000936 · Cited by 12
Cited by
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Shultz, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00686 · Cited by 434
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
Metadata
- Authors
- Lipinski, C. A.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 101
- Pages
- 34-41
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2345340078
- Cited by
- 609
- References
- 50
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.